UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Category: Published Research

Cell-free DNA reveals distinct pathology of multisystem inflammatory syndrome in children

Journal of Clinical Investigation Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening hyperinflammatory condition induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes pediatric COVID-19 (pCOVID-19). The relationship of the systemic tissue injury to the pathophysiology of MIS-C is poorly defined. We leveraged the high sensitivity of epigenomics […]

Nov 14, 2023

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy

Annals of Internal Medicine Compared with untreated persons (n = 55), those taking N-R (n = 72) were older, received more COVID-19 vaccinations, and more commonly had immunosuppression. Fifteen participants (20.8%) taking N-R had VR versus 1 (1.8%) who was untreated (absolute difference, 19.0 percentage points [95% CI, 9.0 to 29.0 percentage points]; P = 0.001). All persons with […]

Nov 14, 2023

The impact of the COVID-19 pandemic on cognitive decline

The Lancet The effect of the COVID-19 pandemic on the general population has been catastrophic. Despite substantial progress in understanding the virology, transmission, and pathogenesis of SARS-CoV-2, many of the long-term consequences of COVID-19 or the restriction measures implemented around the world remain unknown. Evidence for the associated adverse effects of isolation, loneliness, post-traumatic stress, […]

Nov 8, 2023

Masks During Pandemics Caused by Respiratory Pathogens—Evidence and Implications for Action

JAMA More than 3 years after the COVID-19 pandemic began, the use of face masks in the community remains controversial. Vaccination, treatment, population immunity, and other developments have enabled a return to a semblance of prepandemic life, but disagreement about what the evidence shows about masks—and the implications for their use—persists. SARS-CoV-2 is still a […]

Oct 31, 2023

Long-term Prognosis at 1.5 years after Infection with Wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron Variants

International Journal of Infectious Diseases Knowledge is limited on how changing SARS-CoV-2 variants may translate into different characteristics and affect prognosis of patients with long COVID, especially following Omicron variants. We compared long-term prognosis of patients in a Danish Post COVID Clinic infected with wild-type strain, Alpha, Delta, or Omicron variants as well as the […]

Oct 31, 2023

Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans

Annals of Internal Medicine COVID-19 has been linked to the development of many post–COVID-19 conditions (PCCs) after acute infection. Limited information is available on the effectiveness of oral antivirals used to treat acute COVID-19 in preventing the development of PCCs. Eighty-six percent of the participants were male, with a median age of 66 years, and […]

Oct 31, 2023

Long-term health impacts of COVID-19 among 242,712 adults in England

Nature The COVID-19 pandemic is having a lasting impact on health and well-being. We compare current self-reported health, quality of life and symptom profiles for people with ongoing symptoms following COVID-19 to those who have never tested positive for SARS-CoV-2 infection and those who have recovered from COVID-19. Overall, 276,840/800,000 (34·6%) of invited participants took […]

Oct 24, 2023

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Nature Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus, and many will be lethal, and so molnupiravir-induced elevated mutation rates reduce viral load1,2. However, if some patients treated with molnupiravir do […]

Sep 26, 2023

Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis

Nature This review aimed to summarise the relative risk (RR) of the main symptoms of long COVID in people infected with SARS-CoV-2 compared to uninfected controls, as well as the difference in health-related quality of life (HRQoL) after infection. MEDLINE, EMBASE, PubMed, NLM-LitCovid, WHO-COVID-19, arXiv and Europe-PMC were searched up to 23rd March 2022. Studies […]

Sep 19, 2023

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir

Nature Nirmatrelvir is a specific antiviral targeting the main protease (Mpro) of SARS-CoV-2, and has been approved to treat COVID-191,2. As an RNA virus characterized by high mutation rates, whether SARS-CoV-2 will develop resistance to nirmatrelvir is a concern. Our previous studies have shown that several mutational pathways confer resistance to nirmatrelvir but some result […]

Sep 12, 2023